Express Scripts — Caremark RX — Proxy Contest (March 2007)
15 slides from Express Scripts's proxy contest presentation, Mar 12, 2007
Slide 1: ESRX: Innovation and Execution Building on a Proven Record for a Powerful Future
ESRX: Innovation and Execution Building on a Proven Record for a Powerful Future March 2007
Slide 2: Express Scripts Offers Superior Value for Stockholders
Express Scripts Offers Superior Value for Stockholders We believe we will clear anti-trust in a timely manner - additional consideration to compensate for timing of regulatory approval CVS acquisition of Caremark presents significant long-term risks Vertical integrations of PBMs have destroyed value
Slide 3: We Believe We Will Clear Anti-Trust in a Timely Manner
We Believe We Will Clear Anti-Trust in a Timely Manner Number of Fortune 500 Clients, by Service Provider At least 36 unique providers of pharmacy benefits services Notes: Source: Express Scripts Survey of Fortune 500 companies, Mar 2007 "Unknown" reflects 28 companies that did not respond to repeat
Slide 4: Vertical Integrations Destroy Value; Horizontal Integrations Create Value
Vertical Integrations Destroy Value; Horizontal Integrations Create Value Our combination of ESRX and CMX is based on a proven and powerful model that has been repeatedly validated by the market AVG LOSS IN VALUE - - 36% DPS to ESRX Medco Spin-off PCS to Advance Independent PBMs Advance + PCS 2000 A
Slide 5: CVS/CMX Synergies Don't Add Up
CVS/CMX Synergies Don't Add Up Adding PharmaCare's business to CMX's business unlikely to result in $500 million in PBM-specific synergies - translating to an unrealistic $7.00 per Rx CVS/CMX Drugs under management Manufacturer discounts Retail network contracting Direct processing costs/SGA Only pa
Slide 6: CVS Materially Underperforms Relative to Express Scripts in a Down Market
CVS Materially Underperforms Relative to Express Scripts in a Down Market Note: The graph above illustrates stock prices during the time period that corresponds to the S&P 500's peak to trough in the last cycle, which is March 24, 2000 through October 9, 2002. +142% (28%) (49%) Percent Return In a d
Slide 7: Express Scripts vs. CVS Total Shareholder Returns - Since 97
Express Scripts vs. CVS Total Shareholder Returns - Since 1997 Note: Includes dividend reinvestment. Stock Prices through March 8, 2007. $335 $1,695 $189 Ending Value $100 Investment Growth that CMX stockholders enjoyed as independent PBM may disappear with a CVS combination
Slide 8: Ongoing innovation and execution help fuel ESRX's growth
Ongoing innovation and execution in a dynamic environment help fuel ESRX's growth 1990 '91 '92 '93 '94 '95 '96 '97 '98 '99 2000 '01 '02 '03 '04 '05 '06 East 3 6 7.4 21.9 31.1 49.1 66.2 84.9 135.4 243.1 288.5 357.4 439.6 479.4 517.5 563.3 West 30.6 38.6 34.6 31.6 North 45.9 46.9 45 43.9 Retail networ
Slide 9: ESRX Profit Generators Have Room to Run
ESRX Profit Generators Have Room to Run The fundamental business model is strong and proven Ongoing innovation and execution ESRX's fundamental business model continues to produce outstanding results for stockholders, plan sponsors and patients Generics Mail Specialty Today 5 5 5 Potential 55 55 55
Slide 10: ESRX Confirms Bullish Outlook by Increasing 2007 Earnings Guidance
ESRX Confirms Bullish Outlook by Increasing 2007 Earnings Guidance Increased EPS range from $4.08 to $4.20 to a range of $4.14 to $4.26 Midpoint reflects growth of 28% over 2006 Original 2007 guidance provided in Nov. 2006 was $3.90 to $4.02 Increase guidance due to Greater success with mid year cli
Slide 11: We have a track record of outperforming our peers
We have a track record of outperforming our peers PBM Earnings Growth Comparison 2005 2006 2007* ESI 0.34 0.27 0.28 Caremark 0.349 0.23 0.2 Medco 0.088 0.18 0.205 * Reflects the midpoint of guidance. Express Scripts 2007 guidance includes an allowance for the potential impact of the AWP settlement *
Slide 12: ESRX Offers Significant Upside With or Without CMX
ESRX Offers Significant Upside With or Without CMX ESRX stock price offers significant upside if P/E multiples return to historical averages. ESRX PE Multiple 5-Year Avg 3-Year Avg 1-Year Avg Current* ESRX 19.5 20.3 21.8 18.3 West 30.6 38.6 34.6 Baseline - $500 million Lower PBM and specialty pharma
Slide 13: ESRX and CMX: The power of independence and proven value generation
ESRX and CMX The power of independence and proven value generation Powerful strategic rationale Identifiable and achievable synergies Strong free cash flow allowing for rapid debt reduction and share repurchase Superior currency and certainty of value Management team with history of earnings growth,
Slide 14: Forward-looking statements
This presentation contains "forward-looking statements," including, among other statements, statements regarding the proposed business combination between Express Scripts and Caremark, and the anticipated consequences and benefits of such transaction. Statements made in the future tense, and words s
Slide 15: Safe Harbor: Forward Looking Statements - Important Information
Safe Harbor: Forward Looking Statements IMPORTANT INFORMATION Express Scripts has filed a proxy statement in connection with Caremark's special meeting of stockholders at which the Caremark stockholders will consider the CVS Merger Agreement and matters in connection therewith. Express Scripts stock